Get to know our clinical trials
A randomized, double-blind, phase 2b comparative clinical trial investigating the efficacy and safety of visugromab compared with placebo
THE OBJECTIVE OF THIS STUDY IS TO DETERMINE THE SAFETY AND EFFICACY OF A NEW DRUG CALLED “VISUGROMAB” WHEN ADMINISTERED IN COMBINATION WITH IMMUNOCHEMOTHERAPY
Specialist
Medical Oncology Department
Navarre headquarters
Technical Summary
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF VISUGROMAB COMPARED WITH PLACEBO, WHEN BOTH ARE ADMINISTERED IN COMBINATION WITH PEMBROLIZUMAB, PEMETREXED, AND CISPLATIN/CARBOPLATIN, IN PARTICIPANTS WITH NEWLY DIAGNOSED METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
- Code EudraCT: 2024-516792-32
- Protocol number: CTL-002-003
- Promoter: CatalYm GmbH
- Molecule/Drug: Visugromab (CTL-002) versus placebo (administrado en combinación con inmunoquimioterapia)
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.